Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU

Completed · Phase 2

Conditions studied: Staphylococcus

In brief

The purpose of this study is to determine whether or not mupirocin treatment results in S. aureus decolonization in affected NICU patients.

Key facts

Study ID

NCT02967432

Run by

Crouse Hospital

People needed

216

Starts

2016-10-01

Expected to finish

2019-12-01

Last updated by the study team

2020-12-21

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Infants admitted to Crouse Hospital NICU with MSSA/MRSA colonization that have parental consent for participation obtained within 2 days of their initial positive screen.

You may not qualify if…

• Any infant with an active or previous S. aureus infection at time of initial positive S. aureus colonization screen.
• Any infant with a condition thought to be fatal/irreversible (pulmonary hypoplasia, chromosomal/genetic syndromes, fatal cardiac anomalies).
• Any infant with a congenital condition that would prevent specimen collection or treatment application (cleft lip/palate, choanal atresia, abdominal wall defects, imperforate anus, etc.).
• Sufficient length of NICU admission will be necessary to adequately measure the primary outcome. Therefore, enrolled patients will only be included in data analysis if they remain in the NICU until after at least one subsequent MSSA/MRSA screening is performed following completion of their initial treatment course with either mupirocin or placebo.

Where it is running

• Crouse Hospital - Neonatal Intensive Care Unit — Syracuse, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.